Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Lupin Limited has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters span 6 distinct examiners and 6 distinct art units, showing that the portfolio’s active prosecution is distributed across separate examination assignments.
SEAMAN, D MARGARET M is the busiest examiner, with 1 pending action. Counsel may benefit from matter-specific response planning, since the data does not indicate concentration in a shared art unit or examiner group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| ALAWADI, SARAH | 1 | 37.7% | +38.3% |
| WOODWARD, VALERIE LYNN | 1 | 71.3% | +27.1% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
| YOUNG, MICAH PAUL | 1 | 55.2% | +30.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681334 | STABILIZED SOLID ORAL PHARMACEUTICAL COMPOSITION OF VARENICLINE | ALAWADI, SARAH | — |
| 18488743 | BREATH ACTUATED INHALER | WOODWARD, VALERIE LYNN | — |
| 18276567 | PROCESS FOR THE PURIFICATION OF MONOCLONAL ANTIBODIES | LEONARD, ARTHUR S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681334 | STABILIZED SOLID ORAL PHARMACEUTICAL COMPOSITION OF VARENICLINE | ALAWADI, SARAH | — |
| 18488743 | BREATH ACTUATED INHALER | WOODWARD, VALERIE LYNN | — |
| 18276567 | PROCESS FOR THE PURIFICATION OF MONOCLONAL ANTIBODIES | LEONARD, ARTHUR S | — |
| 17789343 | Pharmaceutical Composition of CASR Modulators and Methods and Uses Thereof | YOUNG, MICAH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1619 | 1 |
| 3785 | 1 |
| 1631 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18639693 | STABLE PHARMACEUTICAL COMPOSITION OF METHYLNALTREXONE FOR AN ORAL ADMINISTRATION | SEAMAN, D MARGARET M | 1625 | §102 | Final Rejection | — | Pending | Apr 18, 2024 |
| 18681334 | STABILIZED SOLID ORAL PHARMACEUTICAL COMPOSITION OF VARENICLINE | ALAWADI, SARAH | 1619 | §102§103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18488743 | BREATH ACTUATED INHALER | WOODWARD, VALERIE LYNN | 3785 | §102§103 | Final Rejection | — | Pending | Oct 17, 2023 |
| 18276567 | PROCESS FOR THE PURIFICATION OF MONOCLONAL ANTIBODIES | LEONARD, ARTHUR S | 1631 | §103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 17789343 | Pharmaceutical Composition of CASR Modulators and Methods and Uses Thereof | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | — | Pending | Jun 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLupin Limited has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
D Margaret M Seaman has the most, with 1 of Lupin Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
